Zaleplon

Routes
Oral (PO)
Half-Life (t½)
PO: 1.05h
Formula
C17H15N5O
Molecular Weight
305.34 g/mol
PubChem CID
5719
Aliases
Sonata, Starnoc

Pharmacological Mechanism

Z-drug pyrazolopyrimidine — positive allosteric modulator at GABA-A BZD site, selective for α1 subunit. Used for sleep onset (very short t½ ~1 h limits middle-of-night dosing risk). Mostly metabolized by aldehyde oxidase + CYP3A4. Rapid absorption.

Half-Life & Elimination Curve (PO: 1.05h)

100%50%25%12.5%0%0h0×t½1.05h1×t½2.1h2×t½3.15h3×t½4.2h4×t½5.25h5×t½0×t½ (0h): 100% remaining (~18 µg/L)1×t½ (1.05h): 50% remaining (~9.02 µg/L)2×t½ (2.1h): 25% remaining (~4.51 µg/L)3×t½ (3.15h): 12.5% remaining (~2.25 µg/L)4×t½ (4.2h): 6.3% remaining (~1.13 µg/L)5×t½ (5.25h): 3.1% remaining (~0.564 µg/L)
Plasma (PO)t½ Decay (1.05h)Effect Site (ke0)
  • 0×t½0h100% (18 µg/L)
  • 1×t½1.05h50% (9.02 µg/L)
  • 2×t½2.1h25% (4.51 µg/L)
  • 3×t½3.15h12.5% (2.25 µg/L)
  • 4×t½4.2h6.3% (1.13 µg/L)
  • 5×t½5.25h3.1% (0.564 µg/L)
Elimination t½1.05h (PO)
Rate Constant (ke)0.66 h⁻¹
Time to Peak (Tmax)59m
Est. Peak (Cmax)18 µg/L
Clearance (CL)58.8 L/h
97% Washout (5×t½)5.25h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References